FDA warned Molluscumaway LLC that its molluscum patches, ointment, and body wash are unapproved new drugs.
What happened
FDA reviewed the company's website and Facebook and Instagram pages in July 2023. FDA found the site offered MolluscumAway Hydrating Patches, Little Skins Smoothing Skin Ointment, and Little Skins Gentle Body Wash with claims that they treat molluscum contagiosum. FDA says these are unapproved new drugs, meaning drugs sold without FDA approval, and that no approved application is in effect.
What FDA found
The products are drugs because the website and social media claims say they diagnose, cure, mitigate, treat, or prevent molluscum contagiosum.
section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)The products are new drugs because they are not generally recognized as safe and effective for those claimed uses.
section 201(p) of the FD&C Act, 21 U.S.C. 321(p)The products are marketed without an FDA-approved application, so introducing them into interstate commerce violates the unapproved new drug provisions.
sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)
What FDA wants
FDA asks the company to respond in writing within fifteen working days with the specific steps taken to correct the violations and prevent recurrence. If the company cannot complete corrections in that time, FDA asks it to explain the delay and state when it will finish.
Who should pay attention
- parents and caregivers of children with skin lesions
- sellers of children's skin-care products
- brands making molluscum or skin-lesion treatment claims
This is a summary. Read the original letter on fda.gov.